{"title":"CNB-CSIC开发的MVA-CoV2-S疫苗具有高度免疫原性,对SARS-CoV-2/COVID-19完全有效:未来和机遇","authors":"J. García-Arriaza, Mariano Esteban Rodríguez","doi":"10.53519/analesranf.2022.88.05.08","DOIUrl":null,"url":null,"abstract":"The appearance of a new emerging virus at the end of 2019, later identified as SARS-CoV-2, which rapidly spread to the human population causing the COVID-19 pandemic (with more than 639 million people infected and more than 6.6 million deaths by November 2022), was a great challenge for science, with serious consequences for the human health system and global economy. In record time, different types of vaccines were produced that demonstrated their safety and efficacy in clinical trials and whose administration to the population has been essential for curbing the pandemic, avoiding infections, hospitalizations and deaths. Our laboratory at the CNB-CSIC has been very active in this race, generating a vaccine candidate based on the poxvirus vector termed modified vaccinia virus Ankara (MVA), which demonstrated in three animal models (mouse, hamster and rhesus macaque) its high safety, robust immunogenicity and full efficacy against SARS-CoV-2 infection. This article describes the steps that we follow it up from the beginning of the pandemic to culminate in the industrial development of a very promising vaccine candidate. The next phase is clinical trials in humans. We also discuss about other vaccines, future and opportunities in the medium-long term.\n\nKeywords: MVA; SARS-CoV-2/COVID-19: vaccine; immunogenicity; efficacy; animal models","PeriodicalId":50795,"journal":{"name":"Anales De La Real Academia Nacional De Farmacia","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The MVA-CoV2-S vaccine developed at the CNB-CSIC is highly immunogenic and completely effective against SARS-CoV-2/COVID-19: future and opportunities\",\"authors\":\"J. García-Arriaza, Mariano Esteban Rodríguez\",\"doi\":\"10.53519/analesranf.2022.88.05.08\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The appearance of a new emerging virus at the end of 2019, later identified as SARS-CoV-2, which rapidly spread to the human population causing the COVID-19 pandemic (with more than 639 million people infected and more than 6.6 million deaths by November 2022), was a great challenge for science, with serious consequences for the human health system and global economy. In record time, different types of vaccines were produced that demonstrated their safety and efficacy in clinical trials and whose administration to the population has been essential for curbing the pandemic, avoiding infections, hospitalizations and deaths. Our laboratory at the CNB-CSIC has been very active in this race, generating a vaccine candidate based on the poxvirus vector termed modified vaccinia virus Ankara (MVA), which demonstrated in three animal models (mouse, hamster and rhesus macaque) its high safety, robust immunogenicity and full efficacy against SARS-CoV-2 infection. This article describes the steps that we follow it up from the beginning of the pandemic to culminate in the industrial development of a very promising vaccine candidate. The next phase is clinical trials in humans. We also discuss about other vaccines, future and opportunities in the medium-long term.\\n\\nKeywords: MVA; SARS-CoV-2/COVID-19: vaccine; immunogenicity; efficacy; animal models\",\"PeriodicalId\":50795,\"journal\":{\"name\":\"Anales De La Real Academia Nacional De Farmacia\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anales De La Real Academia Nacional De Farmacia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53519/analesranf.2022.88.05.08\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anales De La Real Academia Nacional De Farmacia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53519/analesranf.2022.88.05.08","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
The MVA-CoV2-S vaccine developed at the CNB-CSIC is highly immunogenic and completely effective against SARS-CoV-2/COVID-19: future and opportunities
The appearance of a new emerging virus at the end of 2019, later identified as SARS-CoV-2, which rapidly spread to the human population causing the COVID-19 pandemic (with more than 639 million people infected and more than 6.6 million deaths by November 2022), was a great challenge for science, with serious consequences for the human health system and global economy. In record time, different types of vaccines were produced that demonstrated their safety and efficacy in clinical trials and whose administration to the population has been essential for curbing the pandemic, avoiding infections, hospitalizations and deaths. Our laboratory at the CNB-CSIC has been very active in this race, generating a vaccine candidate based on the poxvirus vector termed modified vaccinia virus Ankara (MVA), which demonstrated in three animal models (mouse, hamster and rhesus macaque) its high safety, robust immunogenicity and full efficacy against SARS-CoV-2 infection. This article describes the steps that we follow it up from the beginning of the pandemic to culminate in the industrial development of a very promising vaccine candidate. The next phase is clinical trials in humans. We also discuss about other vaccines, future and opportunities in the medium-long term.
Keywords: MVA; SARS-CoV-2/COVID-19: vaccine; immunogenicity; efficacy; animal models
期刊介绍:
The Anales de la Real Academia Nacional de Farmacia� embraces all aspects of pharmaceutical sciences and is a quarterly journal that publishes basic and applied research on pharmaceutical sciences and related areas. It is a medium for reporting selected original and significant contributions to new pharmaceutical knowledge.